News About: R&D


Development of generics focusing on metabolism, cardiovascular system and central nervous system

The National Institute of Food and Drug Safety Evaluation(NIFDS) at Ministry of Food and Drug Safety announced the number of generic products approved was similar to the last year even though the number of approvals o...

Pharmas continue this R&D this year too

New drug development will continue. Major Korean pharmaceutical companies have a plan to export new drug pipelines and commercialize them. In order to export, transfer and commercialize technology, they have more act...

Bill will be prepared for KPA’s ethics commission to make request to revoke license

A bill will be prepared to allow the Korean Pharmaceutical Association(KPA) Ethics Commission to make a request to the Ministry of Health and Welfare to cancel the license of pharmacist who are diagnosed mental illnes...

Biobetter jointly developed with Ildong, ‘ublituximab’ completed part 1 of Phase 2 clinical trial

The development of ‘ublituximab(TG-1101),’ a TG Therapeutics’ monoclonal antibody biobetter, jointly conducted with Ildong Pharmaceutical(CEO Woong-Seup Yoon), passed the part 1 of the Phase 2 clinical trial in the U....

KDRA & KIRAMS sign ‘New Drug Development Agreement’

The Korea Drug Research Association(Chairman Dong-Yeon Kim, KDRA) and the Korea Institute of Radiological & Medical Sciences’(KIRAMS) Advanced Concept Medical Technology Development Platform Building Project Team(Team...

‘Remote dispenser’ completed with examination, to be introduced to vice ministers’ meeting

The Office of Legislation’s examination for remote drug dispensers was finished. Their name was officially finalized as ‘Video Drug Vending Machine.’ According to the Ministry of Health and Welfare(MFDS), the Office ...

Alteogen challenges to KRW 2 trillion hemophilia biomedicine ‘NovoSeven’

Alteogen Inc.(CEO Soon-Jae Park) held an agreement ceremony on the 29th of November as its long-acting hemophilia treatment being developed, ‘ALT-Q2,’ was selected as a project to develop a substance candidate for a p...

Nature Cell acquires approval of Phase 1/2 clinical trials for dementia treatment from US FDA

Clinical trials to treat American Alzheimer’s disease patients with stem cells manufactured in Korea were approved by the U.S. FDA. Nature Cell(CEO Jung-Chan La) announced it acquired approval of the Astrostem’s Phas...

Development trend in modified drugs, ‘complex antidiabetics’

The Korean pharmaceutical companies’ development trend of modified drugs was analyzed as development of complex antidiabetics. According to the Ministry of Food and Drug Safety’s Online Drug Library, the number of dr...

What are vaccines to keep eye on for shingles?

The number of shingles patients has been increasing, and most of them are actually the middle-aged and elders. Thus, companies actively developing vaccines seem to be busy proving rate of prevention in the elder group...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.